Impact of the COVID-19 Pandemic on the Economy, Supply and Sales
First written in FY2020-Q1. 4 of 13 entries say "Restated". Latest entry: FY2024.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
- FY2024MitigatedAnnual report
「The cosmetics raw-materials market is expected to continue recovering in Japan as the impact of COVID-19 fades, society returns to normal and inbound demand increases.」
The disclosure stated that the impact of COVID-19 on the cosmetics market and business activity had dissipated, indicating that the specific risk from COVID-19 was easing. - FY2023-Q3MitigatedAnnual report
「During the third quarter of the fiscal year under review, from 1 December 2022 to 31 August 2023, the Japanese economy began to show signs of recovery as economic activity continued to normalize from the pandemic and the employment and income environment improved, supported by the effects of various government policies.」
The disclosure indicated that economic activity was normalizing from the pandemic and showing signs of recovery, with the deterioration in the economic environment caused by COVID-19 easing. - FY2023-Q2MitigatedAnnual report
「During the second quarter of the fiscal year under review, from 1 December 2022 to 31 May 2023, the Japanese economy showed some weakness due to rising prices, supply-side constraints and volatility in the financial and capital markets, but was gradually recovering, supported by the lifting of border-control measures related to COVID-19 and the effects of various government policies.」
The economic environment was described as gradually recovering, partly because border-control measures related to COVID-19 had been lifted. - FY2023-Q1WorsenedAnnual report
「In addition to the negative impact of COVID-19, higher resource prices stemming from geopolitical uncertainty around the world and soaring energy costs,」
The negative impact of COVID-19 was cited as a continuing factor hindering the recovery of consolidated earnings. - FY2022MitigatedAnnual report
「Against this backdrop, we have made accounting estimates, including impairment of fixed assets and the recoverability of deferred tax assets, on the assumption that the impact of the spread of COVID-19 on our business activities is limited.」
While acknowledging that the impact of COVID-19 remained uncertain, the company shifted to an assumption that its impact on business activities would be limited. - FY2022-Q1RestatedAnnual report
「During the first-quarter consolidated cumulative period ended 28 February 2022 (1 December 2021 to 28 February 2022), Japan's economy showed some weakness, although it continued to recover, amid lingering severe conditions due to COVID-19 and uncertainty related to the situation in Ukraine and other factors.」
While the difficult economic environment caused by COVID-19 continued, signs of recovery were also noted. - FY2021-Q3Continued difficult economic conditions and gradual recoveryAnnual report
「Although conditions remained difficult due to the impact of COVID-19, the economy was gradually recovering, supported by the effects of various government policies and improving overseas economies while measures were taken to prevent the spread of infection.」
The disclosure stated that the difficult economic environment caused by COVID-19 continued, but that the economy was gradually recovering due to the effects of government policies and improving overseas economies. - FY2021-Q2WorsenedAnnual report
「The pharmaceutical CDMO market was also experiencing delays in pharmaceutical development and other issues because of difficulties securing clinical-trial participants.」
The impact of COVID-19 continued, appearing in lower numbers of medical consultations and prescription volumes, as well as delays in pharmaceutical development at CDMOs. - FY2021-Q1RestatedAnnual report
「During the first quarter of the fiscal year under review, from 1 December 2020 to 28 February 2021, the Japanese economy remained in a difficult situation due to the impact of COVID-19, but showed signs of recovery, supported by the effects of various government policies and improving overseas economies.」
The disclosure continued to describe a difficult economic and business environment due to COVID-19, while also noting signs of recovery resulting from the effects of government policies and improving overseas economies. - FY2020RestatedAnnual report
「In particular, in the HBC and food business, cosmetics performed poorly due to lower inbound demand and restrictions on going out as a result of COVID-19. In other businesses, although the impact was limited to certain areas, the effect on business performance was limited in part because of contributions from capturing demand related to the response to COVID-19.」
While the impact of COVID-19 was significant in cosmetics and other products in the HBC and food business, the disclosure stated that the impact on other businesses was limited because they captured demand related to the response to the pandemic. - FY2020-Q3RestatedAnnual report
「We will continue to closely monitor developments in the impact of the spread of COVID-19 on our business.」
The company indicated that it would continue to monitor developments in the impact of COVID-19 on its business. The businesses continued to be affected by declining demand, voluntary suspension of sales activities and postponed delivery dates. - FY2020-Q2MaterialisedAnnual report
「In the pharmaceutical raw materials market, the impact of COVID-19 became apparent in the form of fewer hospital prescriptions, delays in delivery and additional transport costs for imported raw materials, and moves to switch to domestic procurement.」
The impact of COVID-19 became evident in demand for, imports of and procurement of pharmaceutical raw materials. Declining demand and restrictions on sales activities were also reported in the HBC and food, chemicals and pharmaceutical businesses. - FY2020-Q1First statedAnnual report
「In the fine chemicals business, amid delays in delivery and difficulty procuring overseas raw materials due to the spread of COVID-19, the Group promoted multiple sourcing of raw materials to meet firm demand for pharmaceutical raw materials.」
The disclosure described not only downside risks to the economy from COVID-19 but also its actual business impacts, including delays and difficulty in procuring overseas raw materials, restrictions on visits to medical institutions and a decline in inbound consumption.